Management of hairy cell leukaemia in pregnancy

Based on this study's findings, Hairy Cell Leukaemia (HCL) often causes severe thrombocytopenia, which significantly increases the likelihood of Caesarean sections. The researchers noted that only 46.1% of patients birthed vaginally, with many surgical deliveries requiring general anesthesia to manage low platelet counts and bleeding risks.

According to the study's authors, Interferon-alpha (IFN-α) was the most prominent intervention, administered to 23% of the thirteen reviewed patients. This biological therapy was utilized at varying doses to manage the malignancy while attempting to minimize potential adverse effects on the developing fetus during gestation.

The investigators used Ovid MEDLINE and EMBASE to conduct a comprehensive literature search for cases involving Hairy Cell Leukaemia (HCL) and pregnancy. This methodological choice enabled the identification of thirteen rare cases, allowing for a detailed review of treatments like Cladribine, Rituximab, and laparoscopic splenectomy.

The researchers identified that bleeding complications occurred in 50% of the documented cases. This finding highlights a significant limitation in managing Hairy Cell Leukaemia (HCL) during pregnancy, as disease-induced cytopenias create high risks for hemorrhage during both the antenatal period and the delivery process.

The study's authors propose that the outcome aims for pregnant women with Hairy Cell Leukaemia (HCL) should remain the same as those for non-pregnant patients. They conclude that while management is difficult, multidisciplinary care allows these patients to be treated safely without compromising maternal or neonatal health.